BTIG Reiterates Buy on Opus Genetics, Maintains $12 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $12 price target.

Comments

No comments yet. Be the first!